| Identification | Back Directory | [Name]
Benzamide, N-[(1S)-2-[(4-chlorophenyl)amino]-1-methyl-2-oxoethoxy]-3,5-bis(trifluoromethyl)- | [CAS]
2319939-24-5 | [Synonyms]
Benzamide, N-[(1S)-2-[(4-chlorophenyl)amino]-1-methyl-2-oxoethoxy]-3,5-bis(trifluoromethyl)- | [Molecular Formula]
C18H13ClF6N2O3 | [MOL File]
2319939-24-5.mol | [Molecular Weight]
454.75 |
| Chemical Properties | Back Directory | [density ]
1.469±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 10 mg/ml; DMSO: 10 mg/ml; DMSO:PBS (pH 7.2)(1:5): 0.15 mg/ml; Ethanol: 0.25 mg/ml | [pka]
12.58±0.70(Predicted) |
| Hazard Information | Back Directory | [Description]
(S)-CCG-1423 is a stereoisomer of CCG-1423 , a Rho inhibitor that blocks signaling through myocardin-related transcription factor A (MRTF-A) and serum response factor (SRF).1,2 The S-isomer of CCG-1423 inhibits MRTF-A-dependent cellular events, including SRF-mediated gene expression and cell migration, more potently than the R-isomer.2 | [Uses]
(S)-CCG-1423 is an inhibitor of Rho signaling that blocks the nuclear import of MRTF-A. (S)-CCG-1423 reduces the nuclear accumulation of MRTF-A and improves glucose uptake and tolerance in insulin-resistance mice in vivo. (S)-CCG-1423 exhibits higher inhibition activity than the SR- and the R-isomers of CCG-1423 (HY-13991). (S)-CCG-1423 can be used for the research of cancer and diabetes[1]. | [References]
1. Evelyn, C.R., Wade, S.M., Wang, Q., et al. CCG-1423: A small-molecule inhibitor of RhoA transcriptional signaling Mol. Cancer Ther. 6(8),2249-2260(2007).
2. Watanabe, B., Minami, S., Ishida, H., et al. Stereospecific inhibitory effects of CCG-1423 on the cellular events mediated by myocardin-related transcription factor A PLoS One 10(8),(2015). |
|
|